LY-3113593

N/A

Report date: 2022/07/20 14:14:15

Base Information

Drug NameLY-3113593
Drug Alias NameLY-3113593
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionBone morphogenetic protein 6 inhibitors
TargetsBone morphogenetic protein 6
Therapy Area/IndicationsKidney Failure, ChronicRenal Insufficiency, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsKidney Failure, ChronicRenal Insufficiency, Chronic

Other Information

ATC CodeN/A
Related LinksN/A